Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib plus nab-paclitaxel for metastatic castration-resistant prostate cancer (mCRPC)
ChiCTR2300077034Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and paclitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Oct 2023; status: recruiting.
02
Drugs
fluzoparibpaclitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2300077034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077034.